# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Yigal Nochomovitz maintains Ardelyx (NASDAQ:ARDX) with a Buy and lowers the price target from $14 to $10.
Ardelyx shares are trading lower Tuesday after the company announced it has chosen not to apply to include XPHOZAH in the Cente...
Ardelyx's analysis of the CMS policy to include oral-only medicines in the PPS and the Calendar Year 2025 ESRD PPS Proposed...
Cantor Fitzgerald analyst Louise Chen reiterates Ardelyx (NASDAQ:ARDX) with a Overweight.
Piper Sandler analyst Christopher Raymond maintains Ardelyx (NASDAQ:ARDX) with a Overweight and maintains $15 price target.